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Background
Melanoma is a highly malignant melanocyte-derived
tumor and its incidence is increasing at outstanding rate.
Despite specific therapies have been explored for many
years, no effective therapeutic options have been devel-
oped. Vaccination strategies, including Dendritic Cells
(DC) based immunotherapy, are consistently increasing
the proportion of cancer patients with anti-vaccine
immune responses although the number of patients with
increased overall survival is still limited. The efficacy of
the immunotherapy is mainly dependent on tumor
microenvironment –immune system interactions.
Our aim is to evaluate the host immune response to
melanoma by quantifying the density and location of
T cells in primary tumors of patients treated with DC
immunotherapy and correlate them with clinical vari-
ables such as overall survival (OS).
Materials and methods
We collected 60 FFPE primary tumors from melanoma
patients treated with DC immunotherapy. Serial sections
(4 micron in thickness) were stained with CD3, CD8
and CD45RO antibodies. Haematoxylin was used as a
counterstain and Nova Red for the immunohistochem-
ical stain. All the slides were digitalized and an auto-
mated quantitative analysis was performed in order to
evaluate the density and location of two lymphocyte
populations, cytotoxic (CD8) and memory (CD45RO)
T cells. Of all samples the clinical outcome of the
patient is known.
Results
The immunohistochemical analysis of primary mela-
noma using a small set of patients resulted in significant
differences between short (OS<12 months) and long
survivors (OS>24 months). A high degree of T cells
infiltration was seen in the tumor area of both patients,
responding and non-responding to DC immunotherapy.
However, the location but not the density of TILs was
significantly different in the two cohorts of patients and
showed a strong correlation with clinical response to
DC vaccination.
Conclusions
Immune cells within melanoma tumors may have a
prognostic value and clinical significance as a predictor
of patient outcome and response to DC immunotherapy
in melanoma patients.
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